BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 10942925)

  • 1. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
    Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
    Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H; Wierzbowska A; Robak T
    Eur Cytokine Netw; 2003; 14(1):40-51. PubMed ID: 12799213
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
    Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.
    Robak E; Woźniacka A; Sysa-Jedrzejowska A; Stepień H; Robak T
    Eur Cytokine Netw; 2001; 12(3):445-52. PubMed ID: 11566625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
    Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenic protein expression in advanced epithelial ovarian cancer.
    Barton DP; Cai A; Wendt K; Young M; Gamero A; De Cesare S
    Clin Cancer Res; 1997 Sep; 3(9):1579-86. PubMed ID: 9815846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma.
    Neben K; Moehler T; Egerer G; Kraemer A; Hillengass J; Benner A; Ho AD; Goldschmidt H
    Clin Cancer Res; 2001 Sep; 7(9):2675-81. PubMed ID: 11555579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival.
    Andersen NF; Standal T; Nielsen JL; Heickendorff L; Borset M; Sørensen FB; Abildgaard N
    Br J Haematol; 2005 Jan; 128(2):210-7. PubMed ID: 15638855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are basic fibroblast growth factor and vascular endothelial growth factor prognostic indicators in pediatric patients with malignant solid tumors?
    Tabone MD; Landman-Parker J; Arcil B; Coudert MC; Gerota I; Benbunan M; Leverger G; Dosquet C
    Clin Cancer Res; 2001 Mar; 7(3):538-43. PubMed ID: 11297245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between serum levels of vascular endothelial growth factor, hepatocyte growth factor and matrix metalloproteinase-9 with biochemical markers of bone disease in multiple myeloma.
    Alexandrakis MG; Sfiridaki A; Miyakis S; Pappa C; Kandidaki E; Alegakis A; Margioris AN
    Clin Chim Acta; 2007 Apr; 379(1-2):31-5. PubMed ID: 17234170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Coexpression of VEGF and bFGF is associated with increased vascular density in head and neck carcinomas].
    Riedel F; Götte K; Schwalb J; Bergler W; Hörmann K
    Laryngorhinootologie; 2000 Dec; 79(12):730-5. PubMed ID: 11199455
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
    Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
    Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levels of angiogenic peptides in sera from patients with carcinoid tumours during alpha-interferon treatment.
    Nilsson A; Janson ET; Eriksson B; Larsson A
    Anticancer Res; 2001; 21(6A):4087-90. PubMed ID: 11911297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiogenesis in multiple myeloma.
    Jakob C; Sterz J; Zavrski I; Heider U; Kleeberg L; Fleissner C; Kaiser M; Sezer O
    Eur J Cancer; 2006 Jul; 42(11):1581-90. PubMed ID: 16797965
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
    Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
    Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma.
    Tosi P; Zamagni E; Cellini C; Ronconi S; Patriarca F; Ballerini F; Musto P; Di Raimondo F; Ledda A; Lauria F; Masini L; Gobbi M; Vacca A; Ria R; Cangini D; Tura S; Baccarani M; Cavo M
    Haematologica; 2002 Apr; 87(4):408-14. PubMed ID: 11940485
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet number and interleukin-6 correlate with VEGF but not with bFGF serum levels of advanced cancer patients.
    Salgado R; Vermeulen PB; Benoy I; Weytjens R; Huget P; Van Marck E; Dirix LY
    Br J Cancer; 1999 May; 80(5-6):892-7. PubMed ID: 10360671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients.
    Brattström D; Bergqvist M; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Brodin O; Wagenius G
    Anticancer Res; 1998; 18(2A):1123-7. PubMed ID: 9615776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Levels of angiogenic factors in patients with multiple myeloma correlate with treatment response.
    Pour L; Svachova H; Adam Z; Almasi M; Buresova L; Buchler T; Kovarova L; Nemec P; Penka M; Vorlicek J; Hajek R
    Ann Hematol; 2010 Apr; 89(4):385-9. PubMed ID: 19784651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.